Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
04
03
2021
revised:
30
03
2021
accepted:
30
03
2021
pubmed:
28
4
2021
medline:
28
4
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
The trans-membrane protease serine 2 (TMPRSS2) is essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy and safety of TMPRSS2 inhibitors in patients with coronavirus disease 2019 (Covid-19) have not been evaluated in randomized trials. We conducted an investigator-initiated, double-blind, randomized, placebo-controlled multicenter trial in patients hospitalized with confirmed SARS-CoV-2 infection from April 4, to December 31, 2020. Within 48 h of admission, participants were randomly assigned in a 2:1 ratio to receive the TMPRSS2 inhibitor camostat mesilate 200 mg three times daily for 5 days or placebo. The primary outcome was time to discharge or clinical improvement measured as ≥2 points improvement on a 7-point ordinal scale. Other outcomes included 30-day mortality, safety and change in oropharyngeal viral load. 137 patients were assigned to receive camostat mesilate and 68 to placebo. Median time to clinical improvement was 5 days (interquartile range [IQR], 3 to 7) in the camostat group and 5 days (IQR, 2 to 10) in the placebo group ( Under this protocol, camostat mesilate treatment was not associated with increased adverse events during hospitalization for Covid-19 and did not affect time to clinical improvement, progression to ICU admission or mortality. ClinicalTrials.gov Identifier: NCT04321096. EudraCT Number: 2020-001200-42.
Sections du résumé
BACKGROUND
BACKGROUND
The trans-membrane protease serine 2 (TMPRSS2) is essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy and safety of TMPRSS2 inhibitors in patients with coronavirus disease 2019 (Covid-19) have not been evaluated in randomized trials.
METHODS
METHODS
We conducted an investigator-initiated, double-blind, randomized, placebo-controlled multicenter trial in patients hospitalized with confirmed SARS-CoV-2 infection from April 4, to December 31, 2020. Within 48 h of admission, participants were randomly assigned in a 2:1 ratio to receive the TMPRSS2 inhibitor camostat mesilate 200 mg three times daily for 5 days or placebo. The primary outcome was time to discharge or clinical improvement measured as ≥2 points improvement on a 7-point ordinal scale. Other outcomes included 30-day mortality, safety and change in oropharyngeal viral load.
FINDINGS
RESULTS
137 patients were assigned to receive camostat mesilate and 68 to placebo. Median time to clinical improvement was 5 days (interquartile range [IQR], 3 to 7) in the camostat group and 5 days (IQR, 2 to 10) in the placebo group (
INTERPRETATION
CONCLUSIONS
Under this protocol, camostat mesilate treatment was not associated with increased adverse events during hospitalization for Covid-19 and did not affect time to clinical improvement, progression to ICU admission or mortality. ClinicalTrials.gov Identifier: NCT04321096. EudraCT Number: 2020-001200-42.
Identifiants
pubmed: 33903855
doi: 10.1016/j.eclinm.2021.100849
pii: S2589-5370(21)00129-2
pmc: PMC8060682
doi:
Banques de données
ClinicalTrials.gov
['NCT04321096']
Types de publication
Journal Article
Langues
eng
Pagination
100849Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Dr. Mortensen reports a Gilead Travel Grant, outside the submitted work. Dr Østergaard reports personal fees from GlaxoSmithKlinePharma A/S, Gilead Science Denmark A/S, Pfizer A/S, MSD Denmark A/S, and Sanofi Pasteur Europe, outside the submitted work. Dr. Kjolby reports grants from The Lundbeck Foundation, during the conduct of the study; and has or has had stocks in Genmab, Novo Nordisk, Novartis, Amgen, and Regeneron. All other authors have nothing to disclose.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Crit Care Explor. 2020 Nov 16;2(11):e0284
pubmed: 33225308
Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):204-212
pubmed: 33176395
BMJ. 2020 Mar 12;368:m1036
pubmed: 32165426
Future Med Chem. 2020 Sep;12(17):1579-1601
pubmed: 32564623
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Physiol Rev. 2020 Oct 1;100(4):1455-1466
pubmed: 32496872
Pancreatology. 2006;6(5):440-9
pubmed: 16847381
JAMA. 2020 Dec 1;324(21):2149-2150
pubmed: 33175121
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
Int J Infect Dis. 2020 Jul;96:500-502
pubmed: 32470602
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Crit Care. 2020 Jul 3;24(1):392
pubmed: 32620147
FASEB J. 2008 Mar;22(3):659-61
pubmed: 17942826
Antiviral Res. 2015 Apr;116:76-84
pubmed: 25666761
N Engl J Med. 2020 Dec 10;383(24):2333-2344
pubmed: 33085857
EBioMedicine. 2021 Mar;65:103255
pubmed: 33676899
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246
pubmed: 32134909
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677